cabozantinib,atezolizumab
roche
['contact-03', 'rcc,(-irccs),(-srcc),(-urcc)']
perhaps one of the most practice orienting trial presented by . post-progression io not useful in rcc. translation to other tumor sites? #asco23 #contact-03 
Husband, father of 2, oncologist, marathoner, ultrarunner. Trains to inspire and works to push back limits of cancer treatment.